View ValuationSartorius 향후 성장Future 기준 점검 4/6Sartorius (는) 각각 연간 20.7% 및 8.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.4% 로 예상됩니다.핵심 정보20.7%이익 성장률16.16%EPS 성장률Life Sciences 이익 성장20.2%매출 성장률8.8%향후 자기자본이익률17.41%애널리스트 커버리지Good마지막 업데이트22 May 2026최근 향후 성장 업데이트공시 • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.공시 • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.공시 • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.공시 • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.공시 • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.공시 • Jul 21Sartorius Aktiengesellschaft Confirms Consolidated Financial Guidance for the Year 2022Sartorius Aktiengesellschaft confirmed consolidated financial guidance for the year 2022. Consolidated sales revenue is expected to increase by about 15% to 19%, with non-organic growth from acquisitions projected to contribute about 2% points.모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • 17hNow 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 2.2% to €234. The fair value is estimated to be €295, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.Buy Or Sell Opportunity • Apr 23Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 18% to €213. The fair value is estimated to be €271, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.New Risk • Apr 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 7.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.1% average weekly change). Minor Risk High level of debt (91% net debt to equity).Declared Dividend • Mar 16Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 33%. Cash payout ratio: 13%.New Risk • Feb 17New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. This is currently the only risk that has been identified for the company.공시 • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (95% net debt to equity). Share price has been volatile over the past 3 months (4.6% average weekly change).Declared Dividend • Feb 13Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.Declared Dividend • Feb 09Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.공시 • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.공시 • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.Buy Or Sell Opportunity • Feb 04Now 22% undervaluedOver the last 90 days, the stock has risen 9.5% to €245. The fair value is estimated to be €315, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.2% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.공시 • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026공시 • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.공시 • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026New Risk • Dec 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 5.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.2% average weekly change). Minor Risk High level of debt (95% net debt to equity).Buy Or Sell Opportunity • Dec 12Now 21% undervaluedOver the last 90 days, the stock has risen 26% to €244. The fair value is estimated to be €310, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.Reported Earnings • Oct 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €843.2m (up 6.3% from 3Q 2024). Net income: €43.8m (up 209% from 3Q 2024). Profit margin: 5.2% (up from 1.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe.공시 • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.New Risk • Sep 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (96% net debt to equity). Share price has been volatile over the past 3 months (4.6% average weekly change).Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €884.3m (up 2.7% from 2Q 2024). Net income: €32.5m (up 35% from 2Q 2024). Profit margin: 3.7% (up from 2.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks High level of debt (93% net debt to equity). Share price has been volatile over the past 3 months (6.3% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin).공시 • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)New Risk • May 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.5% average weekly change). Minor Risks High level of debt (93% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin).공시 • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.Reported Earnings • Apr 16First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: €0.70. Revenue: €883.0m (up 7.7% from 1Q 2024). Net income: €48.5m (up 32% from 1Q 2024). Profit margin: 5.5% (up from 4.5% in 1Q 2024). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.공시 • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.Buy Or Sell Opportunity • Mar 20Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €241. The fair value is estimated to be €303, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.Declared Dividend • Mar 17Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st April 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 9%.Buy Or Sell Opportunity • Mar 03Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €236. The fair value is estimated to be €298, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.New Risk • Feb 19New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.5% net profit margin).공시 • Feb 18Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025.Reported Earnings • Feb 17Full year 2024 earnings released: EPS: €1.21 (vs €3.00 in FY 2023)Full year 2024 results: EPS: €1.21 (down from €3.00 in FY 2023). Revenue: €3.38b (flat on FY 2023). Net income: €84.0m (down 59% from FY 2023). Profit margin: 2.5% (down from 6.0% in FY 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.Declared Dividend • Feb 17Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st April 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 65%. Cash payout ratio: 11%.공시 • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.공시 • Jan 28+ 1 more updateSartorius Aktiengesellschaft to Report Nine Months, 2025 Results on Oct 16, 2025Sartorius Aktiengesellschaft announced that they will report nine months, 2025 results on Oct 16, 2025공시 • Jan 14+ 1 more updateSartorius Aktiengesellschaft to Report Fiscal Year 2024 Final Results on Feb 17, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 final results on Feb 17, 2025공시 • Nov 16Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025Buy Or Sell Opportunity • Nov 06Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.9% to €229. The fair value is estimated to be €289, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings are also forecast to grow by 37% per annum over the same time period.Reported Earnings • Oct 17Third quarter 2024 earnings releasedThird quarter 2024 results: EPS: €0.21. Revenue: €793.6m (down 2.1% from 3Q 2023). Net income: €14.2m (up 65% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.공시 • Sep 19Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin. Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024.Reported Earnings • Jul 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €860.7m (up 3.4% from 2Q 2023). Net income: €23.9m (down 75% from 2Q 2023). Profit margin: 2.8% (down from 11% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Buy Or Sell Opportunity • May 16Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 18% to €277. The fair value is estimated to be €355, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.Reported Earnings • Apr 18First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: €819.6m (down 9.3% from 1Q 2023). Net income: €36.7m (down 61% from 1Q 2023). Profit margin: 4.5% (down from 10% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.Upcoming Dividend • Mar 26Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 02 April 2024. Payment date: 04 April 2024. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Austrian dividend payers (5.8%). Lower than average of industry peers (0.6%).Declared Dividend • Feb 19Dividend of €0.74 announcedShareholders will receive a dividend of €0.74. Ex-date: 2nd April 2024 Payment date: 4th April 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 25%. Cash payout ratio: 17%.Reported Earnings • Feb 18Full year 2023 earnings released: EPS: €3.00 (vs €9.91 in FY 2022)Full year 2023 results: EPS: €3.00 (down from €9.91 in FY 2022). Revenue: €3.40b (down 19% from FY 2022). Net income: €205.2m (down 70% from FY 2022). Profit margin: 6.0% (down from 16% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.공시 • Feb 03Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024공시 • Jan 26+ 2 more updatesSartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024Sartorius Aktiengesellschaft announced that they will report Q3, 2024 results on Oct 17, 2024공시 • Jan 18Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €257, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 25x in the Life Sciences industry in Europe. Total loss to shareholders of 36% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €238 per share.공시 • Oct 20Sartorius Aktiengesellschaft, Annual General Meeting, Mar 28, 2024Sartorius Aktiengesellschaft, Annual General Meeting, Mar 28, 2024.Reported Earnings • Oct 20Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €810.7m (down 23% from 3Q 2022). Net income: €8.60m (down 94% from 3Q 2022). Profit margin: 1.1% (down from 15% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Oct 17Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €265, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €251 per share.공시 • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.공시 • Aug 06+ 1 more updateSartorius Announces Executive Board ChangesSartorius appointed Florian Funck as Member of the Sartorius Executive Board, effective April 1, 2024. Funck succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann's departure and until Funck takes over, Sartorius CEO Joachim Kreuzburg will assume the responsibilities on an interim basis.Reported Earnings • Jul 26Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €832.0m (down 20% from 2Q 2022). Net income: €95.0m (down 43% from 2Q 2022). Profit margin: 11% (down from 16% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €359, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 27x in the Life Sciences industry in Europe. Total returns to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €224 per share.Reported Earnings • Apr 23First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: €1.36. Revenue: €903.2m (down 12% from 1Q 2022). Net income: €93.1m (down 55% from 1Q 2022). Profit margin: 10% (down from 20% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.Upcoming Dividend • Mar 23Upcoming dividend of €1.44 per share at 0.4% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Austrian dividend payers (5.5%). Lower than average of industry peers (0.7%).Reported Earnings • Feb 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €4.17b (up 21% from FY 2021). Net income: €678.1m (up 113% from FY 2021). Profit margin: 16% (up from 9.2% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.공시 • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.공시 • Jan 04Sartorius Announces Management Changes for Sartorius North AmericaSartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland.Valuation Update With 7 Day Price Move • Nov 10Investor sentiment improved over the past weekAfter last week's 21% share price gain to €401, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 126% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €201 per share.공시 • Oct 20+ 1 more updateSartorius Aktiengesellschaft, Annual General Meeting, Mar 29, 2023Sartorius Aktiengesellschaft, Annual General Meeting, Mar 29, 2023.공시 • Oct 19+ 4 more updatesSartorius Aktiengesellschaft to Report Nine Months, 2023 Results on Oct 19, 2023Sartorius Aktiengesellschaft announced that they will report nine months, 2023 results on Oct 19, 2023공시 • Jul 21Sartorius Aktiengesellschaft Confirms Consolidated Financial Guidance for the Year 2022Sartorius Aktiengesellschaft confirmed consolidated financial guidance for the year 2022. Consolidated sales revenue is expected to increase by about 15% to 19%, with non-organic growth from acquisitions projected to contribute about 2% points.공시 • Feb 11Sartorius AG Proposes Ordinary Dividend for the Year 2021The Supervisory Board of Sartorius AG resolved at its meeting held on February 10, 2022 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Shareholders' Meeting on March 25, 2022, to pay dividends of 1.26 euros per preference share and 1.25 euros per ordinary share. Under this proposal, the total distributed profit would be 85.9 million euros. In the prior year, dividends were 0.71 euros per preference share and 0.70 euros per ordinary share.공시 • Jan 28Sartorius Aktiengesellschaft Provides Consolidated Sales Revenue Guidance for the Fiscal Year 2022 and Reaffirms Consolidated Sales Revenue for the Year 2025Sartorius Aktiengesellschaft provided consolidated sales revenue guidance for the fiscal year 2022. The company expects dynamic performance for the full year of 2022 as well. Consolidated sales revenue is thus projected to increase by about 14% to 18%. Regarding pandemic-related business, the company projects sales revenue for 2022 at about the previous year's level of around EUR 500 million.The consolidated sales revenue target for 2025 had already been substantially raised at the beginning of 2021 and remains unchanged at around EUR 5 billion. The mid-term targets for 2025 still do not include any pandemic-related business as management currently considers such estimates to be too uncertain.공시 • Dec 17Sartorius Aktiengesellschaft (XTRA:SRT) entered into an agreement to acquire a 62.5% stake in ALS Automated Lab Solutions GmbH.Sartorius Aktiengesellschaft (XTRA:SRT) entered into an agreement to acquire a 62.5% stake in ALS Automated Lab Solutions GmbH on December 16, 2021. Sartorius Aktiengesellschaft (XTRA:SRT) is initially purchasing 62.5 percent of the shares in ALS Automated Lab Solutions GmbH. The remaining 37.5 percent will be acquired in 2026. ALS Automated Lab Solutions GmbH currently employs around 30 people and is expected to generate sales in the high single-digit million-euro area in 2021, with a double-digit EBITDA margin.공시 • Jul 07Sartorius Provides Earnings Guidance for the First Half Ended June 30, 2021Sartorius provided earnings guidance for the first half ended June 30, 2021. For the first six months ended June 30, 2021, the company expects revenue growth to be approximately 60% in constant currencies. Revenue of the Bioprocess Solutions Division is anticipated to grow by around 63%.공시 • Jul 06Sartorius Raises Group Earnings Guidance for the Full Year 2021Sartorius raised group earnings guidance for the full year 2021. The company now projects consolidated sales growth of around 45% (previously 35%). For the Bioprocess Solutions Division, sales are anticipated to increase by about 50% (previously 40%). Sales growth for the Lab Products & Services Division is now expected to be 30% (previously 20%).공시 • Jul 04Sartorius Plans to Acquire Remaining Shares of CellgenixSartorius Aktiengesellschaft (XTRA:SRT) has initially acquired 51% of Cellgenix, which has been privately owned until now, for around EUR 100 million in cash. Sartorius strengthens product portfolio for cell and gene therapies by acquiring a majority stake in Cellgenix. At beginning of 2023 and 2026, Sartorius plans to acquire remaining shares of Cellgenix.공시 • Apr 23Sartorius AG Raises Revenue Guidance for the Year 2021Sartorius AG raised revenue guidance for 2021. For the period, the management confirmed its growth forecast for fiscal 2021, which had been raised in mid-March based on very strong order intake and high demand anticipated to continue in the further course of the year. Accordingly, management projects consolidated sales growth of around 35% (of which 5.5% points are expected to be contributed by acquisitions and about 16% points by business related to the coronavirus pandemic).공시 • Mar 19Sartorius Revises Earnings Guidance for the Year 2021Sartorius revised earnings guidance for the year 2021. Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, the company has raised its growth forecast for both divisions and, therefore, for the entire Group for fiscal 2021. Against the backdrop of higher sales expectations and significant economies of scale, the company's earnings outlook has also been raised. Management now projects consolidated sales growth of around 35% (previously 19% to 25%) and an underlying EBITDA margin1 of about 32% (previously about 30.5%) for the Group.공시 • Jan 27Sartorius Aktiengesellschaft to Report Fiscal Year 2020 Final Results on Feb 18, 2021Sartorius Aktiengesellschaft announced that they will report fiscal year 2020 final results on Feb 18, 2021공시 • Oct 20+ 1 more updateSartorius Aktiengesellschaft to Report Q1, 2021 Results on Apr 21, 2021Sartorius Aktiengesellschaft announced that they will report Q1, 2021 results at 5:00 AM, GMT Standard Time on Apr 21, 2021공시 • Sep 26+ 1 more updateSartorius Aktiengesellschaft (XTRA:SRT) agreed to acquire just over 50% stake in Biological Industries Israel Beit Haemek Ltd. from Kibbutz Beit Haemek and Fortissimo Capital, L.P. managed by Fortissimo Capital for approximately €45 million.Sartorius Aktiengesellschaft (XTRA:SRT) agreed to acquire just over 50% stake in Biological Industries Israel Beit Haemek Ltd. from Kibbutz Beit Haemek and Fortissimo Capital, L.P. managed by Fortissimo Capital for approximately €45 million on December 5, 2019. The consideration will be paid in cash. Sartorius Aktiengesellschaft has an option to acquire a further 20% stake in Biological Industries Israel Beit Haemek Ltd. within three years. The transaction is subject to customary closing conditions and is expected to be finalized by mid-December 2019.공시 • Sep 25Sartorius Aktiengesellschaft to Report Q3, 2020 Results on Oct 20, 2020Sartorius Aktiengesellschaft announced that they will report Q3, 2020 results on Oct 20, 2020공시 • Jul 30Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire certain businesses from Danaher Corporation (NYSE:DHR) for approximately $750 million on October 18, 2019. The consideration will be paid in cash and will be subject to closing process. The business consists of label-free biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses. The label-free biomolecular characterization business will become part of Sartorius’ bioanalytics unit within its Lab Products & Services division. The chromatography hardware and resins business will be part of Bioprocess Solutions division. Sartorius Stedim Biotech will acquire parts of Danaher’s Life Science portfolio. Out of the total purchase price of $750 million, about a quarter will be allocated to the businesses purchased by Sartorius Stedim Biotech. Pursuant to conditions set by the antitrust authorities, the portfolio of businesses to be acquired was expanded to include certain businesses associated with single-use tangential flow filtration systems (including flow kits) and stainless steel hollow fiber tangential flow filtration systems. These businesses will ultimately be a part of the Sartorius Bioprocess Solutions Division. Due to this expanded scope, the purchase price was increased by around $75 million to approximately $825 million. BNP Paribas is financing the transaction, acting as sole lead arranger, bookrunner and underwriter. The business reported revenues of approximately $140 million in 2018. Danaher entered into the agreement to sell these businesses as a step towards obtaining regulatory approval for its pending acquisition of the Biopharma business of General Electric Company (NYSE:GE). The closing of this transaction is conditioned upon Danaher's closing its acquisition of the GE Biopharma business. The transaction is also subject to customary closing conditions, antitrust clearance and approvals from various regulatory authorities. In December 2019, the transaction received conditional clearance for the acquisition from the European Commission. On March 18, 2020 and March 19, 2020 respectively, the European Commission and the U.S. Federal Trade Commission cleared the proposed acquisition and the completion is still subject to clearance by the Chinese antitrust enforcement authority of Sartorius as the buyer of the assets. The transaction is expected to close in the first quarter of 2020. As of March 20, 2020, the transaction is expected to close in second quarter of 2020. Michael P. Brueck, James Jian Hu, Francisco J. Morales Barrón and Daniel E. Wolf of Kirkland & Ellis LLP acted as legal advisors for Danaher. Michael Bernhardt, Roland Hlawaty, Scott Golenbock, Christoph Rothenfusser, Alexander Rinne and Fiona Schaeffer of Milbank LLP acted as legal advisor to Sartorius Aktiengesellschaft (XTRA:SRT) in the transaction. Johannes Tieves of Hengeler Mueller advised BNP Paribas on financing of the transaction. Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR) on April 30, 2020.이익 및 매출 성장 예측WBAG:SRT3 - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20284,5073857211,1261912/31/20274,1063305841,0152212/31/20263,752258443839223/31/20263,554163443887N/A12/31/20253,538155395837N/A9/30/20253,517134479874N/A6/30/20253,468104575919N/A3/31/20253,444967121,070N/A12/31/20243,38184566976N/A9/30/20243,32478479924N/A6/30/20243,34178350838N/A3/31/20243,312149144697N/A12/31/20233,396206294854N/A9/30/20233,608358215821N/A6/30/20233,850495204807N/A3/31/20234,053566182744N/A12/31/20224,175678212734N/A9/30/20224,035534175690N/A6/30/20223,880489243723N/A3/31/20223,683434414837N/A12/31/20213,449319466873N/A9/30/20213,183372422770N/A6/30/20212,908332439737N/A3/31/20212,617254350627N/A12/31/20202,336210271512N/A9/30/20202,151181312503N/A6/30/20201,989154227427N/A3/31/20201,901165171385N/A12/31/20191,827157N/A377N/A9/30/20191,768171N/A337N/A6/30/20191,702166N/A318N/A3/31/20191,637153N/A312N/A12/31/20181,566141N/A245N/A9/30/20181,518138N/A245N/A6/30/20181,460126N/A244N/A3/31/20181,426115N/A223N/A12/31/20171,405115N/A207N/A9/30/20171,37691N/A185N/A6/30/20171,37796N/A182N/A3/31/20171,341105N/A173N/A12/31/20161,300103N/A170N/A9/30/20161,25099N/A145N/A6/30/20161,205101N/A112N/A3/31/20161,15996N/A132N/A12/31/20151,11585N/A125N/A9/30/20151,07676N/A160N/A6/30/20151,00361N/A153N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SRT3 의 연간 예상 수익 증가율(20.7%)이 saving rate(2.3%)보다 높습니다.수익 vs 시장: SRT3 의 연간 수익(20.7%)이 Austrian 시장(11.3%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: SRT3 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: SRT3 의 수익(연간 8.8%)이 Austrian 시장(연간 4%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: SRT3 의 수익(연간 8.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SRT3의 자본 수익률은 3년 후 17.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 17:14종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sartorius Aktiengesellschaft는 38명의 분석가가 다루고 있습니다. 이 중 22명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Charles PitmanBarclaysCharles PitmanBarclaysHarry GillisBerenberg35명의 분석가 더 보기
공시 • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
공시 • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
공시 • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
공시 • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.
공시 • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.
공시 • Jul 21Sartorius Aktiengesellschaft Confirms Consolidated Financial Guidance for the Year 2022Sartorius Aktiengesellschaft confirmed consolidated financial guidance for the year 2022. Consolidated sales revenue is expected to increase by about 15% to 19%, with non-organic growth from acquisitions projected to contribute about 2% points.
Buy Or Sell Opportunity • 17hNow 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 2.2% to €234. The fair value is estimated to be €295, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.
Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €899.1m (up 1.8% from 1Q 2025). Net income: €56.2m (up 16% from 1Q 2025). Profit margin: 6.3% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.
Buy Or Sell Opportunity • Apr 23Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 18% to €213. The fair value is estimated to be €271, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.3% over the last 3 years. Earnings per share has declined by 71%. For the next 3 years, revenue is forecast to grow by 8.3% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.
New Risk • Apr 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 7.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.1% average weekly change). Minor Risk High level of debt (91% net debt to equity).
Declared Dividend • Mar 16Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 33%. Cash payout ratio: 13%.
New Risk • Feb 17New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. This is currently the only risk that has been identified for the company.
공시 • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (95% net debt to equity). Share price has been volatile over the past 3 months (4.6% average weekly change).
Declared Dividend • Feb 13Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.
Declared Dividend • Feb 09Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 27th March 2026 Payment date: 31st March 2026 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 11%.
공시 • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
공시 • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
Buy Or Sell Opportunity • Feb 04Now 22% undervaluedOver the last 90 days, the stock has risen 9.5% to €245. The fair value is estimated to be €315, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.2% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
공시 • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026
공시 • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.
공시 • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026
New Risk • Dec 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 5.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.2% average weekly change). Minor Risk High level of debt (95% net debt to equity).
Buy Or Sell Opportunity • Dec 12Now 21% undervaluedOver the last 90 days, the stock has risen 26% to €244. The fair value is estimated to be €310, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.
Reported Earnings • Oct 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €843.2m (up 6.3% from 3Q 2024). Net income: €43.8m (up 209% from 3Q 2024). Profit margin: 5.2% (up from 1.8% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe.
공시 • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
New Risk • Sep 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (96% net debt to equity). Share price has been volatile over the past 3 months (4.6% average weekly change).
Reported Earnings • Jul 24Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €884.3m (up 2.7% from 2Q 2024). Net income: €32.5m (up 35% from 2Q 2024). Profit margin: 3.7% (up from 2.8% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
New Risk • Jul 04New major risk - Revenue and earnings growthEarnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risks High level of debt (93% net debt to equity). Share price has been volatile over the past 3 months (6.3% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin).
공시 • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)
New Risk • May 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 7.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.5% average weekly change). Minor Risks High level of debt (93% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin).
공시 • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
Reported Earnings • Apr 16First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: €0.70. Revenue: €883.0m (up 7.7% from 1Q 2024). Net income: €48.5m (up 32% from 1Q 2024). Profit margin: 5.5% (up from 4.5% in 1Q 2024). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
공시 • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.
Buy Or Sell Opportunity • Mar 20Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €241. The fair value is estimated to be €303, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.
Declared Dividend • Mar 17Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st April 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 61%. Cash payout ratio: 9%.
Buy Or Sell Opportunity • Mar 03Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €236. The fair value is estimated to be €298, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.1% over the last 3 years. Earnings per share has declined by 48%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 27% per annum over the same time period.
New Risk • Feb 19New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.5% net profit margin).
공시 • Feb 18Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025.
Reported Earnings • Feb 17Full year 2024 earnings released: EPS: €1.21 (vs €3.00 in FY 2023)Full year 2024 results: EPS: €1.21 (down from €3.00 in FY 2023). Revenue: €3.38b (flat on FY 2023). Net income: €84.0m (down 59% from FY 2023). Profit margin: 2.5% (down from 6.0% in FY 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
Declared Dividend • Feb 17Dividend of €0.74 announcedDividend of €0.74 is the same as last year. Ex-date: 28th March 2025 Payment date: 1st April 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 65%. Cash payout ratio: 11%.
공시 • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.
공시 • Jan 28+ 1 more updateSartorius Aktiengesellschaft to Report Nine Months, 2025 Results on Oct 16, 2025Sartorius Aktiengesellschaft announced that they will report nine months, 2025 results on Oct 16, 2025
공시 • Jan 14+ 1 more updateSartorius Aktiengesellschaft to Report Fiscal Year 2024 Final Results on Feb 17, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 final results on Feb 17, 2025
공시 • Nov 16Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025
Buy Or Sell Opportunity • Nov 06Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.9% to €229. The fair value is estimated to be €289, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings are also forecast to grow by 37% per annum over the same time period.
Reported Earnings • Oct 17Third quarter 2024 earnings releasedThird quarter 2024 results: EPS: €0.21. Revenue: €793.6m (down 2.1% from 3Q 2023). Net income: €14.2m (up 65% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
공시 • Sep 19Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin. Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024.
Reported Earnings • Jul 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €860.7m (up 3.4% from 2Q 2023). Net income: €23.9m (down 75% from 2Q 2023). Profit margin: 2.8% (down from 11% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Buy Or Sell Opportunity • May 16Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 18% to €277. The fair value is estimated to be €355, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 28% per annum over the same time period.
Reported Earnings • Apr 18First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: €819.6m (down 9.3% from 1Q 2023). Net income: €36.7m (down 61% from 1Q 2023). Profit margin: 4.5% (down from 10% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Upcoming Dividend • Mar 26Upcoming dividend of €0.74 per shareEligible shareholders must have bought the stock before 02 April 2024. Payment date: 04 April 2024. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Austrian dividend payers (5.8%). Lower than average of industry peers (0.6%).
Declared Dividend • Feb 19Dividend of €0.74 announcedShareholders will receive a dividend of €0.74. Ex-date: 2nd April 2024 Payment date: 4th April 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 25%. Cash payout ratio: 17%.
Reported Earnings • Feb 18Full year 2023 earnings released: EPS: €3.00 (vs €9.91 in FY 2022)Full year 2023 results: EPS: €3.00 (down from €9.91 in FY 2022). Revenue: €3.40b (down 19% from FY 2022). Net income: €205.2m (down 70% from FY 2022). Profit margin: 6.0% (down from 16% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
공시 • Feb 03Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024
공시 • Jan 26+ 2 more updatesSartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024Sartorius Aktiengesellschaft announced that they will report Q3, 2024 results on Oct 17, 2024
공시 • Jan 18Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024
Valuation Update With 7 Day Price Move • Nov 06Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €257, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 25x in the Life Sciences industry in Europe. Total loss to shareholders of 36% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €238 per share.
공시 • Oct 20Sartorius Aktiengesellschaft, Annual General Meeting, Mar 28, 2024Sartorius Aktiengesellschaft, Annual General Meeting, Mar 28, 2024.
Reported Earnings • Oct 20Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: €810.7m (down 23% from 3Q 2022). Net income: €8.60m (down 94% from 3Q 2022). Profit margin: 1.1% (down from 15% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Oct 17Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €265, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €251 per share.
공시 • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.
공시 • Aug 06+ 1 more updateSartorius Announces Executive Board ChangesSartorius appointed Florian Funck as Member of the Sartorius Executive Board, effective April 1, 2024. Funck succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann's departure and until Funck takes over, Sartorius CEO Joachim Kreuzburg will assume the responsibilities on an interim basis.
Reported Earnings • Jul 26Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €832.0m (down 20% from 2Q 2022). Net income: €95.0m (down 43% from 2Q 2022). Profit margin: 11% (down from 16% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €359, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 27x in the Life Sciences industry in Europe. Total returns to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €224 per share.
Reported Earnings • Apr 23First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: €1.36. Revenue: €903.2m (down 12% from 1Q 2022). Net income: €93.1m (down 55% from 1Q 2022). Profit margin: 10% (down from 20% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Upcoming Dividend • Mar 23Upcoming dividend of €1.44 per share at 0.4% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Austrian dividend payers (5.5%). Lower than average of industry peers (0.7%).
Reported Earnings • Feb 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €4.17b (up 21% from FY 2021). Net income: €678.1m (up 113% from FY 2021). Profit margin: 16% (up from 9.2% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
공시 • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.
공시 • Jan 04Sartorius Announces Management Changes for Sartorius North AmericaSartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland.
Valuation Update With 7 Day Price Move • Nov 10Investor sentiment improved over the past weekAfter last week's 21% share price gain to €401, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 126% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €201 per share.
공시 • Oct 20+ 1 more updateSartorius Aktiengesellschaft, Annual General Meeting, Mar 29, 2023Sartorius Aktiengesellschaft, Annual General Meeting, Mar 29, 2023.
공시 • Oct 19+ 4 more updatesSartorius Aktiengesellschaft to Report Nine Months, 2023 Results on Oct 19, 2023Sartorius Aktiengesellschaft announced that they will report nine months, 2023 results on Oct 19, 2023
공시 • Jul 21Sartorius Aktiengesellschaft Confirms Consolidated Financial Guidance for the Year 2022Sartorius Aktiengesellschaft confirmed consolidated financial guidance for the year 2022. Consolidated sales revenue is expected to increase by about 15% to 19%, with non-organic growth from acquisitions projected to contribute about 2% points.
공시 • Feb 11Sartorius AG Proposes Ordinary Dividend for the Year 2021The Supervisory Board of Sartorius AG resolved at its meeting held on February 10, 2022 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Shareholders' Meeting on March 25, 2022, to pay dividends of 1.26 euros per preference share and 1.25 euros per ordinary share. Under this proposal, the total distributed profit would be 85.9 million euros. In the prior year, dividends were 0.71 euros per preference share and 0.70 euros per ordinary share.
공시 • Jan 28Sartorius Aktiengesellschaft Provides Consolidated Sales Revenue Guidance for the Fiscal Year 2022 and Reaffirms Consolidated Sales Revenue for the Year 2025Sartorius Aktiengesellschaft provided consolidated sales revenue guidance for the fiscal year 2022. The company expects dynamic performance for the full year of 2022 as well. Consolidated sales revenue is thus projected to increase by about 14% to 18%. Regarding pandemic-related business, the company projects sales revenue for 2022 at about the previous year's level of around EUR 500 million.The consolidated sales revenue target for 2025 had already been substantially raised at the beginning of 2021 and remains unchanged at around EUR 5 billion. The mid-term targets for 2025 still do not include any pandemic-related business as management currently considers such estimates to be too uncertain.
공시 • Dec 17Sartorius Aktiengesellschaft (XTRA:SRT) entered into an agreement to acquire a 62.5% stake in ALS Automated Lab Solutions GmbH.Sartorius Aktiengesellschaft (XTRA:SRT) entered into an agreement to acquire a 62.5% stake in ALS Automated Lab Solutions GmbH on December 16, 2021. Sartorius Aktiengesellschaft (XTRA:SRT) is initially purchasing 62.5 percent of the shares in ALS Automated Lab Solutions GmbH. The remaining 37.5 percent will be acquired in 2026. ALS Automated Lab Solutions GmbH currently employs around 30 people and is expected to generate sales in the high single-digit million-euro area in 2021, with a double-digit EBITDA margin.
공시 • Jul 07Sartorius Provides Earnings Guidance for the First Half Ended June 30, 2021Sartorius provided earnings guidance for the first half ended June 30, 2021. For the first six months ended June 30, 2021, the company expects revenue growth to be approximately 60% in constant currencies. Revenue of the Bioprocess Solutions Division is anticipated to grow by around 63%.
공시 • Jul 06Sartorius Raises Group Earnings Guidance for the Full Year 2021Sartorius raised group earnings guidance for the full year 2021. The company now projects consolidated sales growth of around 45% (previously 35%). For the Bioprocess Solutions Division, sales are anticipated to increase by about 50% (previously 40%). Sales growth for the Lab Products & Services Division is now expected to be 30% (previously 20%).
공시 • Jul 04Sartorius Plans to Acquire Remaining Shares of CellgenixSartorius Aktiengesellschaft (XTRA:SRT) has initially acquired 51% of Cellgenix, which has been privately owned until now, for around EUR 100 million in cash. Sartorius strengthens product portfolio for cell and gene therapies by acquiring a majority stake in Cellgenix. At beginning of 2023 and 2026, Sartorius plans to acquire remaining shares of Cellgenix.
공시 • Apr 23Sartorius AG Raises Revenue Guidance for the Year 2021Sartorius AG raised revenue guidance for 2021. For the period, the management confirmed its growth forecast for fiscal 2021, which had been raised in mid-March based on very strong order intake and high demand anticipated to continue in the further course of the year. Accordingly, management projects consolidated sales growth of around 35% (of which 5.5% points are expected to be contributed by acquisitions and about 16% points by business related to the coronavirus pandemic).
공시 • Mar 19Sartorius Revises Earnings Guidance for the Year 2021Sartorius revised earnings guidance for the year 2021. Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, the company has raised its growth forecast for both divisions and, therefore, for the entire Group for fiscal 2021. Against the backdrop of higher sales expectations and significant economies of scale, the company's earnings outlook has also been raised. Management now projects consolidated sales growth of around 35% (previously 19% to 25%) and an underlying EBITDA margin1 of about 32% (previously about 30.5%) for the Group.
공시 • Jan 27Sartorius Aktiengesellschaft to Report Fiscal Year 2020 Final Results on Feb 18, 2021Sartorius Aktiengesellschaft announced that they will report fiscal year 2020 final results on Feb 18, 2021
공시 • Oct 20+ 1 more updateSartorius Aktiengesellschaft to Report Q1, 2021 Results on Apr 21, 2021Sartorius Aktiengesellschaft announced that they will report Q1, 2021 results at 5:00 AM, GMT Standard Time on Apr 21, 2021
공시 • Sep 26+ 1 more updateSartorius Aktiengesellschaft (XTRA:SRT) agreed to acquire just over 50% stake in Biological Industries Israel Beit Haemek Ltd. from Kibbutz Beit Haemek and Fortissimo Capital, L.P. managed by Fortissimo Capital for approximately €45 million.Sartorius Aktiengesellschaft (XTRA:SRT) agreed to acquire just over 50% stake in Biological Industries Israel Beit Haemek Ltd. from Kibbutz Beit Haemek and Fortissimo Capital, L.P. managed by Fortissimo Capital for approximately €45 million on December 5, 2019. The consideration will be paid in cash. Sartorius Aktiengesellschaft has an option to acquire a further 20% stake in Biological Industries Israel Beit Haemek Ltd. within three years. The transaction is subject to customary closing conditions and is expected to be finalized by mid-December 2019.
공시 • Sep 25Sartorius Aktiengesellschaft to Report Q3, 2020 Results on Oct 20, 2020Sartorius Aktiengesellschaft announced that they will report Q3, 2020 results on Oct 20, 2020
공시 • Jul 30Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire certain businesses from Danaher Corporation (NYSE:DHR) for approximately $750 million on October 18, 2019. The consideration will be paid in cash and will be subject to closing process. The business consists of label-free biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses. The label-free biomolecular characterization business will become part of Sartorius’ bioanalytics unit within its Lab Products & Services division. The chromatography hardware and resins business will be part of Bioprocess Solutions division. Sartorius Stedim Biotech will acquire parts of Danaher’s Life Science portfolio. Out of the total purchase price of $750 million, about a quarter will be allocated to the businesses purchased by Sartorius Stedim Biotech. Pursuant to conditions set by the antitrust authorities, the portfolio of businesses to be acquired was expanded to include certain businesses associated with single-use tangential flow filtration systems (including flow kits) and stainless steel hollow fiber tangential flow filtration systems. These businesses will ultimately be a part of the Sartorius Bioprocess Solutions Division. Due to this expanded scope, the purchase price was increased by around $75 million to approximately $825 million. BNP Paribas is financing the transaction, acting as sole lead arranger, bookrunner and underwriter. The business reported revenues of approximately $140 million in 2018. Danaher entered into the agreement to sell these businesses as a step towards obtaining regulatory approval for its pending acquisition of the Biopharma business of General Electric Company (NYSE:GE). The closing of this transaction is conditioned upon Danaher's closing its acquisition of the GE Biopharma business. The transaction is also subject to customary closing conditions, antitrust clearance and approvals from various regulatory authorities. In December 2019, the transaction received conditional clearance for the acquisition from the European Commission. On March 18, 2020 and March 19, 2020 respectively, the European Commission and the U.S. Federal Trade Commission cleared the proposed acquisition and the completion is still subject to clearance by the Chinese antitrust enforcement authority of Sartorius as the buyer of the assets. The transaction is expected to close in the first quarter of 2020. As of March 20, 2020, the transaction is expected to close in second quarter of 2020. Michael P. Brueck, James Jian Hu, Francisco J. Morales Barrón and Daniel E. Wolf of Kirkland & Ellis LLP acted as legal advisors for Danaher. Michael Bernhardt, Roland Hlawaty, Scott Golenbock, Christoph Rothenfusser, Alexander Rinne and Fiona Schaeffer of Milbank LLP acted as legal advisor to Sartorius Aktiengesellschaft (XTRA:SRT) in the transaction. Johannes Tieves of Hengeler Mueller advised BNP Paribas on financing of the transaction. Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR) on April 30, 2020.